Hot off the Press! - November 2024
Altasciences Supports Metsera in Their Early Stage Clinical Trials for Obesity
Altasciences is proud to have supported Metsera, Inc., a clinical stage biopharmaceutical company, with nonclinical and early-stage clinical trials. This support includes a recent Phase I/II trial of MET-097i: an ultra-long-acting injectable amylin analog and fully biased GLP-1 receptor agonist.
In a trial conducted at our clinic, Metsera reported positive topline results. This study enabled Metsera to initiate a randomized 16-week Phase II trial of MET-097i, which could offer potential new treatment options for those affected by obesity. We also further supported Metsera with our proactive drug development solution, providing nonclinical, bioanalysis, CRO, and program management services for several other therapeutic candidates.
Altasciences Upholds Commitment to Supporting Pharma and Biotech With Comprehensive Bioanalytical Services
A trusted drug development research partner for over 30 years, Altasciences remains committed to providing world-class bioanalytical services in support of the preclinical and clinical studies conducted at our cutting-edge facilities, as well as extensive standalone solutions to meet your diverse needs.
Our flexible bioanalytical services from discovery to Phase IV empower clients across every phase of research.
Let's Promote Your Project!
Interested in a custom press release, written by our experts, to feature the great research we do together? Email us to get started!
You may also be interested in:
- The Altascientist Issue No.42: Managing the Complexities of Glucagon-Like Peptide-1 Receptor Agonist Drug Development
- The Altascientist Issue No.41: Immunomodulation Assessments for Clinical Trials: Sophisticated Bioanalytical Approaches to Support Complex Modalities
- Case Study: GLP-1 RA: Overcoming Known Pharmacological Effects
- Case Study: GLP-1 RA: Rapid Clinical Phase I Study Execution
- Blog: 4 Essential Topics to Cover in Your First CRO Meeting
- Press Releases: View More